Recombinant Factor VIIa for Uncontrolled Bleeding in 2 Different Cases of Coagulopathy
J. Islam, Salman Azhar, J. B. Alperin, Imran Syed
Abstract
Open-access reader
J. Islam, Salman Azhar, J. B. Alperin, Imran Syed
Abstract
Open-access reader
Coagulation factor VIIa (Recombinant) (rF.VIIa; NovoSeven) was approved for use in the United States by the Food and Drug Administration in March 1999 for the treatment of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or factor IX. Off-label use of rF.VIIa to
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Coagulation factor VIIa (Recombinant) (rF.VIIa; NovoSeven) was approved for use in the United States by the Food and Drug Administration in March 1999 for the treatment of bleeding episodes in patients with hemophilia A or B with inhibitors to factor VIII or factor IX. Off-label use of rF.VIIa to
Key concepts: Medicine, Recombinant factor VIIa, Coagulopathy, Factor VIIa, Food and drug administration, Coagulation, Factor VII, Recombinant DNA